Chinese healthcare companies accelerate global expansion through Hong Kong dual listings

Chinese healthcare companies are increasingly turning to A+H dual primary listings in Mainland China and Hong Kong as a strategic mechanism for accessing international capital and funding overseas growth.

According to a report by Asian Business Review, UOB has identified the recent surge in dual listings as a key strategic shift among healthcare firms, with Hong Kong serving as a platform for companies to attract global investors, recruit international talent, and expand beyond China's domestic market. UOB described the trend as "a strategic response to the maturity of the domestic market and the immense opportunities of global expansion."

Edge Medical is among the companies seeing strong overseas-led growth momentum, with cumulative overseas surgical robot installations surpassing 100 units, and approximately 50 units added year-to-date, almost matching full-year 2025 deployments. The company's MSP2000 system received EU approval in October 2025 and NMPA approval in March 2026, supporting its international rollout. In China, Edge Medical's market share has risen to approximately 30%, up from 22% in 2025, narrowing the gap with Da Vinci at roughly 37%, though competition is intensifying with peers including Mindray and United Imaging Healthcare increasing investment in next-generation surgical robotics.

Aier Eye Hospital Group is advancing its overseas strategy through the acquisition of majority stakes in Clínicas do Brasil and Contact-Gel for approximately BRL530 million (€86 million), creating an 81-centre ophthalmology platform across Brazil. Overseas revenue reached $458.43 million (€408 million) in 2025, up 16.5% year-on-year and accounting for 13.68% of total revenue.

ByteDance is deepening its healthcare presence through an $887.28 million (€790 million) investment in an AI-powered hospital complex in Beijing, expected to complete by 2029. The project will integrate AI capabilities directly into clinical services and hospital operations, marking a significant move into offline healthcare delivery.

In parallel, ByteDance is spinning off its AI drug discovery unit, Anew Lab, into an independently funded entity while retaining a controlling stake. The platform is developing molecular structure prediction models and an end-to-end AI drug discovery system, with early-stage drug candidates targeting autoimmune conditions including psoriasis and ankylosing spondylitis currently in preclinical development.

Access the complete report and analysis of China's healthcare globalisation strategy at the source.